Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. - Wikidata - awgldk - TriplyDB

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

http://www.wikidata.org/entity/Q34453425

about

Q24186229 Bile acid derivatives for people with primary sclerosing cholangitis Current Management of Alcoholic Hepatitis and Future Therapies The changing faces of cholangitis Recent advances in understanding and managing cholestasis Novel bile acid therapeutics for the treatment of chronic liver diseases Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver Combination antiretroviral studies for patients with primary biliary cirrhosis Primary biliary cirrhosis: From bench to bedside Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection Recent advances in the diagnosis and treatment of primary biliary cholangitis.Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies Farnesoid X Receptor an Emerging Target to Combat Obesity.NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor.Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.Why Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications?Metabolic Profile of Obeticholic Acid and Endogenous Bile Acids in Rats with Decompensated Liver Cirrhosis Functional and structural features of cholangiocytes in health and disease.Therapeutic targeting of bile acids Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis Therapeutic targets for cholestatic liver injury Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules.Proposed therapies in primary biliary cholangitis.Serum Autotaxin is a Marker of the Severity of Liver Injury and Overall Survival in Patients with Cholestatic Liver Diseases.Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge.Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application.Primary biliary cirrhosis: safety and benefits of established and emerging therapies.Autoimmune liver disease: evaluating overlapping and cross-over presentations-a case-based discussion.It is time to change primary biliary cirrhosis (PBC): New nomenclature from "cirrhosis" to "cholangitis", and upcoming treatment based on unveiling pathology.Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes.Obeticholic acid for the treatment of primary biliary cirrhosis.Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.

P2860

Q24186229-57727E91-CE9F-480D-98C6-7CCB9D62DFF6 Q24186230-C34B3ABE-FC0B-4C53-B02D-5196ED3B6588 Q26746544-B9D8AF50-0B69-43FD-9EBC-39126593E44F Q26747051-39BB10FC-895B-4E70-8A55-59BAD398D536 Q26748537-3A37E6FF-4C6A-4F57-97D9-6E5B1E9EF10A Q26748613-A948B665-DEDF-4722-8C62-BB279C24720E Q26766699-36C9FBD4-FE0F-4295-9F42-82009197D90B Q26772310-FF2EB2EF-C6FA-4252-9747-ABE2D2D8578A Q26799419-E1002193-421C-4C00-AD13-A04883C8F3BE Q26800206-7476065B-BD1B-451D-A9FA-7CE8C12524FA Q26853649-1DC5983B-03E4-420F-A5D1-E2DC7E93EC12 Q28066233-64EA55B6-94A5-49A7-871E-0B7EDBC145A5 Q28072209-6384F67E-0F0A-41BE-96D4-715E8ED820DA Q28076353-D8571B4B-F10F-4530-A10F-1D6CD459E5CA Q28118967-743EC053-3538-4DB6-A549-979D7381A8BF Q28831219-F38C5775-AE41-4905-9D0D-F89DDC4D79D0 Q30234444-12A10A10-7E1F-4DC7-937A-20E2A94421BF Q30235507-81807F88-A137-4AFC-8BF1-50F0718107A0 Q30666362-FB1E0849-938B-4FD1-A5C6-A4B227AA120A Q33711736-1744405E-C884-42CE-B522-278131A3BB02 Q33840969-FDC05172-3FAD-4D75-8926-B0DF23AAA364 Q33891552-D832B17E-3C6B-451F-A154-446C128129EF Q35933236-3929E64A-5E80-4627-AF34-5E271FA0533C Q35958534-FF7BEF88-204F-4E08-A08F-88BF80E54DDB Q35979451-6306B5FC-8EB8-4667-81CC-6B791B2976D4 Q36242886-096A23B1-3AC2-465C-9F3D-B95C88A1398C Q36752084-951BC05B-E793-4095-8737-F142EA3AD999 Q36960966-7D81BA70-65A9-4FBB-AF20-7022CCC363EF Q36987335-6055F6BB-22D5-4AB8-99A1-8027E0209503 Q37072380-E794D4EE-B082-4278-93DD-59E0A5180F5C Q37163154-7116BF77-27CE-49D1-B042-125AE09FCBB4 Q37538343-E709D56A-454B-421D-BD1A-85925701CEBA Q37584099-9BB16F98-7ADD-4DD8-91D9-8F2E2FDF9DC2 Q38541491-E5A2D7F9-0185-46FE-96A4-053624295FA5 Q38554677-8894805B-DD00-4F0F-9FE1-A142F4BC3827 Q38608956-5FC4B110-809C-45C2-92A2-FCE97837ACF4 Q38620686-C0D7313D-FB82-44A9-92AA-60ECB24F26D7 Q38626000-E2F55782-1A2B-4317-8F30-8149EB894842 Q38628470-A81890E4-64AC-4A90-8B6B-1543E15B26EA Q38634986-15B8A0E6-AAAF-4F83-B9A4-8CA9E7F595CD

P2860

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

http://www.wikidata.org/entity/Q34453425

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Efficacy of obeticholic acid i ...... ponse to ursodeoxycholic acid.

@ast

Efficacy of obeticholic acid i ...... ponse to ursodeoxycholic acid.

@en

Efficacy of obeticholic acid i ...... ponse to ursodeoxycholic acid.

@nl

type

label

Efficacy of obeticholic acid i ...... ponse to ursodeoxycholic acid.

@ast

Efficacy of obeticholic acid i ...... ponse to ursodeoxycholic acid.

@en

Efficacy of obeticholic acid i ...... ponse to ursodeoxycholic acid.

@nl

prefLabel

Efficacy of obeticholic acid i ...... ponse to ursodeoxycholic acid.

@ast

Efficacy of obeticholic acid i ...... ponse to ursodeoxycholic acid.

@en

Efficacy of obeticholic acid i ...... ponse to ursodeoxycholic acid.

@nl

P1433

Q34453425-D834A975-7C30-4742-A0BB-6F953ECDC71A

P1476

Q34453425-22492973-D2F2-4A1D-9F0A-2FA30F3DA663

P2093

Q34453425-0675A913-BE24-4D93-9352-5648B2AA8F62

Q34453425-32A618F3-5CF2-4CDC-A634-7C79967DA066

Q34453425-333AF2F4-DB11-441B-B08B-DE01C3397B8B

Q34453425-41C867EF-DDE7-4B4A-9FAA-71372E5070FF

Q34453425-52D3DC79-48BF-49EC-BCCD-30DFC906FB95

Q34453425-5ABC06CF-9D2A-4EE3-82C4-DAB89C36E976

Q34453425-6D0F9533-0AED-4D60-8007-D1B758FBC91B

Q34453425-74B42444-9A8E-4B81-862A-9F83A2EBAA54

Q34453425-763A3FF3-FEED-4641-9950-1EF9E69B9B82

Q34453425-A194C9E6-A4BE-46AD-99EE-6BFD1CC5316F

P304

Q34453425-02A083F8-9DBA-4819-850D-E73BF9DC11DF

P31

Q34453425-1BA995B8-85E6-4A7E-A3FE-CA507E02C9C3

P356

Q34453425-3E5C4DA5-5470-4D32-86C9-50B6912C98D6

P407

Q34453425-F8FEE36E-01A7-4FA3-9594-3AF9DCD74A20

P433

Q34453425-C08596CB-7075-4FFB-ADD8-FABEE60A93F8

P478

Q34453425-AD969F20-6B93-440C-BEC3-73484D998D4A

P50

Q34453425-B299D9EC-4D4D-4E74-B87C-F9622498BA27

Q34453425-C2A9F558-22DB-4C54-803E-A2A111AF4771

P577

Q34453425-DE032E09-D5B8-4434-8F25-8E29B3FFF94F

P5875

Q34453425-6B37402C-4557-43A2-A09D-72D281BB10BE

P698

Q34453425-CBE97D6E-51DE-4866-9AA0-4BEDB5CC8EA8

P921

Q34453425-637FA8DC-E8DD-47C8-9FF0-E78F63426454

Q34453425-FDB97C65-C1BC-48C6-B774-6BD6690C78DB

P356

J.GASTRO.2014.12.005

P1433

Gastroenterology

P1476

Efficacy of obeticholic acid i ...... sponse to ursodeoxycholic acid

@en

P2093

Andrew Mason

http://www.w3.org/2001/XMLSchema#string

Catherine Vincent

http://www.w3.org/2001/XMLSchema#string

Cathi Sciacca

http://www.w3.org/2001/XMLSchema#string

David Shapiro

http://www.w3.org/2001/XMLSchema#string

Erin Castelloe

http://www.w3.org/2001/XMLSchema#string

Hanns-Ulrich Marschall

http://www.w3.org/2001/XMLSchema#string

Henry C Bodhenheimer

http://www.w3.org/2001/XMLSchema#string

Keith Lindor

http://www.w3.org/2001/XMLSchema#string

Kris V Kowdley

http://www.w3.org/2001/XMLSchema#string

Luciano Adorini

http://www.w3.org/2001/XMLSchema#string

P304

751-61.e8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2014.12.005

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

148

http://www.w3.org/2001/XMLSchema#string

P50

Gideon M. Hirschfield

P577

2014-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269717884

http://www.w3.org/2001/XMLSchema#string

P698

25500425

http://www.w3.org/2001/XMLSchema#string

P921

obeticholic acid